隶属于 boao biology group co. ltd.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2001
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Chipscreen Biosciences' Chiauranib, combined with a PD-(L)1 monoclonal antibody and chemotherapy, has received approval for a Phase III clinical trial. - The trial will evaluate the combination as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). - Chiauranib's unique mechanism targets angiogenesis, mitosis, and the tumor microenvironment, potentially improving long-term survival in ES-SCLC patients. - A Phase III trial of Chiauranib monotherapy for later-line SCLC is complete, with other trials ongoing for ovarian, breast, and pancreatic cancers.
- Chipscreen Biosciences' Chiauranib, combined with PD-(L)1 antibody and chemotherapy, receives approval for Phase III clinical trials in first-line treatment of extensive-stage small cell lung cancer. - Chiauranib's unique mechanism targets neuroendocrine tumors, enhances immunotherapy and chemotherapy effects through anti-angiogenesis and immune regulation, potentially improving long-term survival. - The Phase III trial of Chiauranib monotherapy for later-line SCLC is completed, with Pre-NDA communication ongoing, alongside other trials for ovarian, triple-negative breast, sarcoma, and pancreatic cancers.
- Chipscreen Biosciences' Chiauranib receives approval for a Phase III clinical trial as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). - The trial will evaluate Chiauranib in combination with a PD-(L)1 monoclonal antibody and standard chemotherapy, potentially improving long-term survival in ES-SCLC patients. - Chiauranib's unique mechanism targets tumor angiogenesis, prevents tumor cell mitosis, and modulates the tumor microenvironment, showing promise in neuroendocrine tumors. - A Phase III trial of Chiauranib monotherapy for later-line SCLC is complete, with other trials progressing for ovarian cancer, triple-negative breast cancer, sarcoma, and pancreatic cancer.
